A study evaluating efficacy and pharmacodynamics of the Human-papillomavirus-vaccine-recombinant-quadrivalent-Merck (Gardasil) in adult men with recurrent laryngeal papillomatosis.
Phase of Trial: Phase IV
Latest Information Update: 01 Jul 2018
At a glance
- Drugs Human papillomavirus vaccine recombinant quadrivalent Merck (Primary)
- Indications Human papillomavirus infections; Recurrent respiratory papillomatosis
- Focus Pharmacodynamics; Therapeutic Use
- 10 Jul 2017 New trial record